TRIUMPH trial programme (revision 1)
Old revision·06:20, 18 Sep 2024·FreightFenna
This is an old revision of this page, as it stood at 06:20, 18 Sep 2024, saved by FreightFenna with the summary create article — trial programme stub. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| TRIUMPH trial programme | |
|---|---|
| Drug | Retatrutide |
| Indications studied | Obesity, type 2 diabetes, related conditions |
| Status | Ongoing; not approved |
| Topic infobox · conventions | |
The TRIUMPH trial programme is the phase 3 series evaluating retatrutide, an investigational triple agonist at the GIP, GLP-1 and glucagon receptors. The compound is not approved in any jurisdiction and the programme is ongoing.[1]
The programme follows a phase 2 obesity trial that reported mean weight change of −24.2% at 48 weeks at the highest dose against −2.1% for placebo. Phase 2 effect sizes in this field have not always been reproduced at phase 3 scale, and this article will require revision as the programme reports.[1]
References
Categories: